947 related articles for article (PubMed ID: 33216852)
1. Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions.
Meyerowitz EA; Sen P; Schoenfeld SR; Neilan TG; Frigault MJ; Stone JH; Kim AY; Mansour MK
Clin Infect Dis; 2021 Jun; 72(12):e1130-e1143. PubMed ID: 33216852
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
3. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection.
Copaescu A; Smibert O; Gibson A; Phillips EJ; Trubiano JA
J Allergy Clin Immunol; 2020 Sep; 146(3):518-534.e1. PubMed ID: 32896310
[TBL] [Abstract][Full Text] [Related]
4. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
5. The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm.
Chau AS; Weber AG; Maria NI; Narain S; Liu A; Hajizadeh N; Malhotra P; Bloom O; Marder G; Kaplan B
Arthritis Rheumatol; 2021 Jan; 73(1):23-35. PubMed ID: 32929876
[TBL] [Abstract][Full Text] [Related]
6. Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial.
Aricò E; Castiello L; Bracci L; Urbani F; Lombardo F; Bacigalupo I; Ancidoni A; Vanacore N; Falcione A; Reggiani C; Dutti GM; Maglie MG; Papa O; Bartoletti PL; Ozzella G; Bevilacqua N; Nicastri E; Belardelli F; Sconocchia G
Trials; 2021 Sep; 22(1):584. PubMed ID: 34479601
[TBL] [Abstract][Full Text] [Related]
7. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.
Schijns V; Lavelle EC
Eur J Immunol; 2020 Jul; 50(7):932-938. PubMed ID: 32438473
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
9. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
10. Current status in cellular-based therapies for prevention and treatment of COVID-19.
Hattab D; Amer MFA; Mohd Gazzali A; Chuah LH; Bakhtiar A
Crit Rev Clin Lab Sci; 2023 Aug; 60(5):321-345. PubMed ID: 36825325
[TBL] [Abstract][Full Text] [Related]
11. Immune Immunomodulation in Coronavirus Disease 2019 (COVID-19): Strategic Considerations for Personalized Therapeutic Intervention.
Hall MW; Joshi I; Leal L; Ooi EE
Clin Infect Dis; 2022 Jan; 74(1):144-148. PubMed ID: 32604407
[TBL] [Abstract][Full Text] [Related]
12. Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus Macaques.
White AD; Sibley L; Sarfas C; Morrison AL; Bewley K; Churchward C; Fotheringham S; Gkolfinos K; Gooch K; Handley A; Humphries HE; Hunter L; Kennard C; Longet S; Mabbutt A; Moffatt M; Rayner E; Tipton T; Watson R; Hall Y; Bodman-Smith M; Gleeson F; Dennis M; Salguero FJ; Carroll M; McShane H; Cookson W; Hopkin J; Sharpe S
Front Immunol; 2021; 12():801799. PubMed ID: 35222355
[TBL] [Abstract][Full Text] [Related]
13. Between immunomodulation and immunotolerance: The role of IFNγ in SARS-CoV-2 disease.
Todorović-Raković N; Whitfield JR
Cytokine; 2021 Oct; 146():155637. PubMed ID: 34242899
[TBL] [Abstract][Full Text] [Related]
14. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
15. Accelerating the Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: A Risk of Combining Dexamethasone and Tocilizumab for Severe Coronavirus Disease 2019.
Koeckerling D; Barker J
J Infect Dis; 2021 Sep; 224(6):934-937. PubMed ID: 34157110
[TBL] [Abstract][Full Text] [Related]
16. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
Wooding DJ; Bach H
Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
[TBL] [Abstract][Full Text] [Related]
17. Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate.
Mehta P; Fajgenbaum DC
Curr Opin Rheumatol; 2021 Sep; 33(5):419-430. PubMed ID: 34264880
[TBL] [Abstract][Full Text] [Related]
18. Diverse Effects of Exosomes on COVID-19: A Perspective of Progress From Transmission to Therapeutic Developments.
Gurunathan S; Kang MH; Kim JH
Front Immunol; 2021; 12():716407. PubMed ID: 34394121
[TBL] [Abstract][Full Text] [Related]
19. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
20. Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation.
Cardone M; Yano M; Rosenberg AS; Puig M
Front Immunol; 2020; 11():1131. PubMed ID: 32574265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
